Erythropoiesis is a dynamic and complex process during which erythroid progenitors develop into enucleated red blood cells (RBCs). This multistep program 1 is tightly regulated to allow for constant replenishment of the highly abundant but short lived RBCs. At steady state, erythropoiesis is orchestrated mainly by erythropoietin (Epo) 2,3 , although several additional growth factors have been implicated in this process [4] [5] [6] [7] [8] [9] [10] [11] . In addition, recent evidence indicates that erythroid development is controlled by the microenvironment of the developing erythroid cells. Erythroid cells have long been described to develop in a specialized niche, the erythroblastic island 12 , which is composed of a central macrophage surrounded by erythroblasts at different stages of maturation 13 . Macrophages within these structures are hypothesized to carry out essential physiological functions, including iron recycling from senescent RBCs and engulfment of nuclei extruded during erythroblast enucleation [13] [14] [15] [16] . Moreover, several lines of data suggest that macrophages also promote the proliferation and survival of maturing erythroblasts [17] [18] [19] [20] [21] [22] . These effects seem to be dependent on erythroblast-macrophage contact 22 , suggesting that adhesion molecules or paracrine factors secreted within the erythroid niche could be important effectors of erythrocyte development. Consistent with this hypothesis, macrophage-or erythroblast-derived factors and a number of adhesion molecules known to be important for erythroblastic island formation have been shown to regulate erythropoiesis, particularly during embryogenesis or under conditions of stress erythropoiesis [9] [10] [11] 14, 18, [23] [24] [25] .
Erythropoiesis is a dynamic and complex process during which erythroid progenitors develop into enucleated red blood cells (RBCs). This multistep program 1 is tightly regulated to allow for constant replenishment of the highly abundant but short lived RBCs. At steady state, erythropoiesis is orchestrated mainly by erythropoietin (Epo) 2, 3 , although several additional growth factors have been implicated in this process [4] [5] [6] [7] [8] [9] [10] [11] . In addition, recent evidence indicates that erythroid development is controlled by the microenvironment of the developing erythroid cells. Erythroid cells have long been described to develop in a specialized niche, the erythroblastic island 12 , which is composed of a central macrophage surrounded by erythroblasts at different stages of maturation 13 . Macrophages within these structures are hypothesized to carry out essential physiological functions, including iron recycling from senescent RBCs and engulfment of nuclei extruded during erythroblast enucleation [13] [14] [15] [16] . Moreover, several lines of data suggest that macrophages also promote the proliferation and survival of maturing erythroblasts [17] [18] [19] [20] [21] [22] . These effects seem to be dependent on erythroblast-macrophage contact 22 , suggesting that adhesion molecules or paracrine factors secreted within the erythroid niche could be important effectors of erythrocyte development. Consistent with this hypothesis, macrophage-or erythroblast-derived factors and a number of adhesion molecules known to be important for erythroblastic island formation have been shown to regulate erythropoiesis, particularly during embryogenesis or under conditions of stress erythropoiesis [9] [10] [11] 14, 18, [23] [24] [25] .
Even though erythropoiesis is an extremely active process, it can be further stimulated under conditions of anemia, a process commonly known as stress erythropoiesis. During stress erythropoiesis, erythroid development extends to extramedullary sites (mainly the spleen and liver), leading to expansion of the erythroid progenitor pool, recruitment of iron and increased reticulocytosis and RBC production 26, 27 . Unlike steady state erythropoiesis, which seems to be relatively insensitive to microenvironmental changes [9] [10] [11] 14, 18, 24, 25 , stress erythropoiesis is highly dependent on integrating signals from the Epo-Epo receptor (EpoR)-Jak2-Stat5 axis [28] [29] [30] and those activated within the erythroblastic island, including Bmp4-Smad5 and integrin signaling [9] [10] [11] 14, 17, 18, [24] [25] [26] 31 . Interestingly, the pathophysiology of several disorders resembles a chronic state of stress erythropoiesis. This includes two seemingly dichotomous diseases, polycythemia vera and β-thalassemia. Polycythemia vera is characterized by extremely elevated erythrocytosis associated with the constitutively active JAK2 V617F mutation [32] [33] [34] [35] [36] . In contrast, β-thalassemia is characterized by anemia (caused by low β-globin synthesis) and expansion of the pool of erythroid progenitors 37, 38 . Furthermore, for both diseases, mouse models and human patients share features characteristic of stress erythropoiesis, including splenomegaly, expansion of the erythroid progenitor pool and elevated reticulocytosis [36] [37] [38] [39] [40] [41] . These features stem from elevated activation of JAK2 downstream of EPOR (arising from the JAK2 V617F mutation in polycythemia vera and elevated serum EPO concentration in β-thalassemia) and can be limited by the administration of JAK2 inhibitors 39, 40, [42] [43] [44] [45] . Even though these disorders are characterized by chronic stress erythropoiesis, in both cases triggered by genetic lesions, the contribution of macrophages to their pathophysiology has not previously been investigated.
In this study we explore the role of macrophages during stress and pathological erythropoiesis. Our results indicate a decisive contribution of macrophages under different stress conditions (anemia, EPO administration, polycythemia vera and β-thalassemia). Notably, macrophage depletion in mouse models of polycythemia vera or β-thalassemia had beneficial effects, reversing key pathological features of both diseases. We further extended these observations to human samples and present evidence supporting the need for direct contact between macrophages and erythroid progenitors, suggesting that macrophage-erythroblast adhesion interactions within the erythroblast island are essential for RBC development in physiological and disease conditions.
RESULTS

Clodronate treatment impairs stress erythropoiesis
To study the role of macrophages during erythropoiesis, we depleted macrophages in vivo by administering clodronate-encapsulated liposomes (referred to hereafter as clodronate) 46 . We confirmed that a single intravenous (i.v.) injection of clodronate eliminated macrophages from the spleen and bone marrow, as determined by a substantial decrease in F4/80 expression in these organs (Online Methods and Supplementary Fig. 1 ). Moreover, in line with a previous report 47 , our data ( Supplementary Fig. 1 ) show that this approach targets various subsets of macrophages, including those coexpressing the macrophage-specific marker F4/80 and vascular cell adhesion molecule 1 (Vcam1). Expression of these two markers identifies macrophages in the erythroblastic islands 48 . Clodronate treatmen did not have noteworthy effects on the percentage of other myeloid lineages in the spleen or bone marrow, suggesting that this approach is specifically targeting the macrophage lineage (Supplementary Fig. 1) .
To investigate the role of macrophages during steady state erythropoiesis, we treated wild-type (WT) mice with clodronate once every 2 weeks for a total of 12 weeks. This treatment induced a mild compensated iron-deficiency anemia that was characterized by decreased hemoglobin concentrations and RBC mean hemoglobin content (MCH), but this treatment did not lead to reduced numbers of RBCs (Supplementary Fig. 2a) , reduced reticulocyte counts (data not shown) or reduced spleen weight and did not cause substantial changes in erythroid profiles as determined by fluorescence-activated cell sorting (FACS) analysis (Supplementary Fig. 2b,c) . The reduction in MCH, which was associated with decreased transferrin saturation (data not shown), indicates that chronic depletion of macrophages at steady state reduces iron availability and hemoglobin synthesis rather than total RBC production. Moreover, clodronate-treated mice had elevated serum Epo concentrations compared to control mice treated with PBS-containing liposomes at the time point at which anemia started to develop (Supplementary Fig. 2d ), demonstrating that anemia was not associated with inappropriate erythropoietin signaling.
Considering the limited contribution of macrophages to steady state erythropoiesis, we investigated the potential impact of macrophage depletion under conditions of increased erythropoiesis. Mice subjected to phlebotomy-induced anemia and treated with clodronate at day 0 showed impaired recovery from anemia with reduced reticulocytosis compared to phlebotomized mice treated with PBS-containing liposomes (Fig. 1a) . This impaired recovery in clodronate-treated mice was associated with limited erythropoiesis in the bone marrow and spleen compared to controls, as determined by flow cytometry ( Fig. 1 and Supplementary Fig. 3a,b) . We treated a second group of mice with clodronate 4 d after the induction of anemia, when elevated erythropoietic activity and splenomegaly were observed (Fig. 1b,c) . Compared to phlebotomized controls, mice treated with clodronate 4 d after anemia induction had a significant reduction in reticulocyte counts, splenomegaly and the percentage of erythroid precursors in the bone marrow and spleen as early as day 6 (Fig. 1a-d and Supplementary Fig. 3c,d ). Clodronate administration in this setting also led to the emergence of a distinguishable CD71 high Ter119 low cell population in the flow cytometry profiles. This cell population consisted primarily of erythroblasts (CD71 high Ter119 low CD45 low ) undergoing cell death ( Fig. 1e and Supplementary Fig. 4) . These results indicate that macrophages are important for both the expansion and maintenance of elevated erythroid activity in conditions of anemia. On the basis of these observations, we also investigated whether macrophages are required to support increased erythroid activity after administration of human recombinant EPO (hrEPO). Indeed, clodronate administration impaired erythroid expansion in the spleen, as well as the production of RBCs and reticulocytes, in response to hrEPO administration (Supplementary Fig. 5 ). Together these data strongly suggest that under conditions of stress erythropoiesis, signals from the erythroid niche complement those downstream of EpoR to fully support erythropoietic activity. In addition, the effects seen in mice treated with hrEPO suggest that these signals act independently from the pathways activated by hypoxia, as these mice do not suffer anemia, unlike those treated by phlebotomy.
Macrophages have been shown to have an important role in the maintenance of normal iron homeostasis, as they recycle iron from senescent RBCs 49 . Considering this, we determined whether the slow recovery from anemia in clodronate-treated mice was associated with decreased iron availability for erythropoiesis. We first analyzed serum iron parameters and found that after phlebotomy, clodronate-treated WT mice had decreased serum iron and transferrin saturation values compared to control mice treated with PBS-containing liposomes (referred to hereafter as PBS) (Supplementary Fig. 6a,b) , corroborating that macrophages have an important role in iron recycling. We next investigated whether impaired recovery from anemia after macrophage depletion could be attributed exclusively to limited iron availability. Considering that dietary iron and hepcidin have been previously shown to have a crucial role during the recovery phase from phlebotomy-induced anemia 27 , we tested whether dietary iron supplementation or genetic mouse models of increased dietary iron uptake (Hfe or Hamp knockout mice) would compensate for iron deficiency after a single dose of clodronate. Clodronate treatment in phlebotomized Hfe knockout, Hamp knockout or WT mice fed an iron-rich diet did not alter iron supply to erythroid cells, as shown by similarly elevated serum iron concentrations during all phases of recovery in PBS-and clodronate-treated mice in each group (Supplementary Fig. 6a,b) . To a limited extent, elevated serum iron parameters did allow the iron-loaded as well as the knockout mice to recover faster from phlebotomy-induced anemia than WT mice fed a regular diet (Supplementary Fig. 6c ). However, compared to WT controls, the faster recovery of hemoglobin values in iron-loaded mice was predominantly associated with elevated MCH rather than an increase in RBC numbers ( Supplementary Fig. 6c-e) . In addition, erythroid expansion in the bone marrow and spleen after phlebotomy npg was impaired in clodronate-treated iron-loaded mice when compared to iron-loaded PBS-treated controls (Supplementary Fig. 7 ). We found a similar difference when comparing clodronate-treated ironloaded with non-iron loaded PBS-treated mice. This effect probably caused the delayed recovery from anemia observed in iron-loaded or non-iron loaded WT mice after clodronate administration when compared to the corresponding controls ( Fig. 1e and Supplementary  Fig. 6c,d ). These observations indicate that elevated serum iron concentrations are largely insufficient to compensate for the absence of macrophages in sustaining erythroid proliferation and RBC synthesis during recovery from anemia. These data support the notion that iron is important to sustain stress erythropoiesis but also that pathways triggered by macrophages are quantitatively important in the erythropoietic response after phlebotomy-induced anemia independently of the role of macrophages in erythroid-iron recycling.
Clodronate improves the phenotype of polycythemia vera Considering the crucial role that macrophages have under conditions of increased erythropoietic activity, we investigated whether macrophages are also involved in the pathophysiology of polycythemia vera using a transgenic line (Jak2 V617F/+ ) carrying a Cre-inducible Jak2 V617F mutation 40 . These mice have a transplantable polycythemia vera-like phenotype, mediated by the constitutive activation of Jak2 (ref. 40) . Accordingly, we generated a cohort of mice with polycythemia vera by engrafting Jak2 V617F/+ VAV-Cre double transgenic bone marrow into WT mice. As early as 2 weeks after engraftment, mice transplanted with Jak2 V617F/+ VAV-Cre double transgenic bone marrow developed features characteristic of polycythemia vera, including elevated hematocrit, increased RBC counts and reticulocytosis. In contrast to PBS-treated mice, weekly clodronate administration beginning 16 d after engraftment rapidly normalized hematocrit and RBC counts in these mice (Fig. 2a) . Furthermore, clodronate-treated mice showed significant evidence of decreased erythropoietic activity, as indicated by reduced reticulocytosis, decreased extramedullary hematopoiesis (EMH) in the bone marrow and spleen, decreased splenomegaly ( Fig. 2b-e) and a reduced number of Epo-independent burst forming units-erythroid (Supplementary Fig. 8) . A similar reduction in erythrocytosis and EMH was achieved when we initiated clodronate administration 2 months after bone marrow transplant (BMT), a point at which the polycythemia vera phenotype is fully established (data not shown). These results indicate that macrophage depletion not only prevents but can also reverse pathology in these mice. Clodronate treatment improves anemia in Hbb th3/+ mice In β-thalassemia, erythropoiesis is constitutively enhanced to compensate for chronic anemia. However, erythropoiesis in this disorder is ineffective and characterized by an increased number of erythroid progenitors that do not generate a sufficient number of RBCs as a consequence of premature cell death and reduced cell differentiation [37] [38] [39] . We investigated how macrophages influence ineffective erythropoiesis in a mouse model of β-thalassemia intermedia (Hbb th3/+ mice) 50 with anemia and splenomegaly. Notably, 40 h after a single clodronate injection, Hbb th3/+ mice showed reduced anemia, characterized by increased hemoglobin concentrations and increased numbers of RBCs as compared to Hbb th3/+ PBS-treated control mice (Fig. 3a) . Moreover, spleen size was significantly decreased by 32% in clodronate-treated compared to PBS-treated Hbb th3/+ mice (Fig. 3b) . The effect on ineffective erythropoiesis and anemia could be seen as early as 20 h after clodronate administration (Supplementary Fig. 9 ). These beneficial effects were not associated with increased apoptosis of erythroid progenitors ( Supplementary Fig. 10 ) but were instead associated with more effective erythropoiesis, as indicated by a reduction in the number of erythroid progenitors and a proportional increase in the number of differentiated erythroid cells in both the spleen and the bone marrow (Fig. 3c,d and Supplementary Figs. 11 and 12) . Consistent with these results, clodronate treatment led to a reduction in the number of cycling erythroblasts in the spleen (Supplementary Fig. 13 ), possibly accounting for the decreased splenomegaly. These results indicate that, paradoxically, macrophages impair efficient erythroid development in β-thalassemia. These changes were associated with increased hepcidin expression in the liver along with decreased serum iron concentrations ( Supplementary Fig. 14) , both of which have been shown to improve ineffective erythropoiesis in Hbb th3/+ mice 51, 52 . Considering that dietary iron absorption in mice accounts for ~50% of the iron in circulation 53, 54 , we hypothesized that dietary iron supplementation could compensate for decreased iron recycling after clodronate administration. To determine whether the improved erythropoiesis after clodronate administration is mediated solely by reduced iron availability 51, 52 , we iron loaded β-thalassemic mice by feeding them a high-iron diet or generated β-thalassemic mice lacking hepcidin expression (Hbb th3/+ Hamp knockout mice). We used the last group of mice because they show increased iron absorption when fed the standard iron diet, representing an alternative approach to increase the iron overload in Hbb th3/+ mice. At steady state, we found that serum iron values were elevated in both models compared to Hbb th3/+ controls. However, unlike in non-iron loaded Hbb th3/+ mice, macrophage depletion in iron-overloaded Hbb th3/+ or Hbb th3/+ Hamp knockout mice did not lead to a decrease in serum iron availability ( Supplementary  Figs. 15a and 16a) . Nevertheless, clodronate administration resulted in improvements in erythroid differentiation ( Supplementary  Figs. 15b-d and 16b-d) and splenomegaly in both groups (a 28% reduction in iron-supplemented Hbb th3/+ mice and a 12% reduction in Hbb th3/+ Hamp knockout mice), suggesting an iron-independent function of macrophages in stimulating erythropoiesis. We also tested whether supplementation of Hbb th3/+ mice with parenteral iron dextran could compensate the reduction of serum iron concentrations associated with clodronate administration. Although this treatment did not increase serum iron or transferrin saturation values at steady state, it prevented a drop in these parameters after clodronate administration in Hbb th3/+ mice (Supplementary Fig. 17a ). Even in this setting, macrophage depletion resulted in a reduction of EMH ( Supplementary  Fig. 17b-d) and splenomegaly (30% reduction). Although the role of iron in ineffective erythropoiesis in β-thalassemia has previously been shown 51, 52 , our data suggest that macrophages contribute to the development of EMH and splenomegaly in this disorder independently of their modulation of erythroid iron availability.
To determine how long-term macrophage depletion affects ineffective erythropoiesis, we administered clodronate to Hbb th3/+ mice for up to 12 weeks. This treatment led to a significant improvement of anemia and red cell distribution width (Fig. 4a) . Furthermore, despite an increase in the number of circulating RBCs in clodronatetreated mice, reticulocyte counts decreased over time, indicating that erythropoietic activity was reduced (Fig. 4a) . This apparent contradiction was resolved when we observed that macrophage depletion increased RBC lifespan to a duration similar to that in WT mice (Fig. 4b) . The increased lifespan of RBCs in clodronate-treated Hbb th3/+ mice was not associated with deficient erythrophagocytosis but with an improvement in RBC characteristics as indicated by a series of additional observations. First, the lifespan of RBCs derived from clodronate-treated Hbb th3/+ mice was significantly extended compared to RBCs derived from PBS-treated Hbb th3/+ mice after transfusion into GFP + transgenic mice, which have an intact reticuloendothelial system and in which endogenous (GFP + ) and (GFP -) RBCs can be distinguished by FACS analysis (Fig. 4c) . Second, RBC morphology was improved (Fig. 4d) . Third, the MCH of the RBCs was decreased in clodronate-treated Hbb th3/+ mice (Fig. 4a) , suggesting that these cells take up less iron, with potential beneficial effects on hemichrome formation 51, 52 . RBCs derived from clodronatetreated Hbb th3/+ mice also had reduced accumulation of α-globin chains in the RBC membrane compared to RBCs from Hbb th3/+ PBStreated control mice (Fig. 4e) .
Chronic clodronate treatment markedly suppressed splenomegaly, with normalization of total spleen size within 2 months as compared to the spleen size of WT mice (Fig. 4f) . The decrease in splenomegaly was erythropoietin independent (Supplementary Fig. 18 ) and was npg associated with a reduction of EMH and a restoration of normal splenic architecture (Fig. 4g,h and Supplementary Fig. 19 ).
Macrophages alter proliferation of human erythroblasts
We investigated how primary human macrophages influence the development of human erythroblasts ex vivo. We expanded hematopoietic progenitors from three patients with polycythemia vera carrying the JAK2 V617F mutation, one patient with β-thalassemia, as well as from four healthy individuals, and evaluated their proliferative potential when differentiated into the erythroid lineage in the presence of their own macrophages. In all three groups, erythroblasts cultured in the presence of macrophages from the same individual showed increased proliferation compared to those cultured alone (Fig. 5a ). This effect was associated with an increased percentage of cell cycling and a decreased percentage of apoptotic erythroblasts ( Fig. 5b and Supplementary Fig. 20) . We next investigated whether direct macrophage-erythroblast contact was required by performing transwell experiments. We found that the positive effect exerted by macrophages on erythroid proliferation was decreased by 75% in transwell cocultures, suggesting that direct macrophage-erythroblast interaction is required (Fig. 5c) , although some secreted factors might also be involved. We then examined the effect of macrophage coculture on erythroid cell surface markers. Macrophages did not have a substantial effect on the morphological appearance of erythroblasts and did not noticeably affect the expression of the erythroblast developmental markers glycophorin A (GPA), CD44, CD117 and the erythrocyte membrane protein Band-3 ( Supplementary Fig. 21) . However, at a later time point (day 8), there was an evident reduction in the number of enucleated erythroblasts in the cocultures, as well as retention of β1 integrin expression by FACS analysis ( Fig. 5d and Supplementary Fig. 22 ). These observations using human samples are consistent with our results in the mouse models and support a model in which macrophages promote erythroid proliferation and survival while slowing down erythroblast differentiation. different tissues 55 . One such function is the regulation of erythroid development 14, 17, 18, 22 . However, the contribution of macrophages to pathological erythropoiesis and the therapeutic potential of targeting macrophage function have not previously been investigated. Our data underscore the central role that macrophages have under conditions of increased erythropoietic activity, such as induced anemia or hrEPO administration. Our current data extend our previous findings that iron availability is crucial for recovery from induced anemia and that an elevated iron supply can be beneficial in conditions of anemia 27 . Moreover, our results show that even under conditions of increased erythroid iron supply, macrophage depletion delays recovery from induced anemia, indicating that macrophages have an important role in supporting stress erythropoiesis independent of their role in providing iron to erythroblasts. Our data demonstrate that even though EPO 3, 56 and iron are rightfully recognized as master regulators of erythropoiesis, they are not sufficient to fully support erythroblast proliferation and survival during stress erythropoiesis. Under such conditions, iron-independent stress erythropoiesis macrophage-supporting activity (SEMA) is also required for normal erythroid activity (Fig. 6) .
DISCUSSION
We further extend the concept of macrophage-dependent erythropoiesis to polycythemia vera and β-thalassemia, pathological conditions associated with elevated erythropoietic activity. Polycythemia vera is a clonal stem cell disorder in which the somatic JAK2 V617F mutation [36] [37] [38] [39] [40] [41] leads to a hyperproliferative phenotype. Although our data do not question the importance of the JAK2 V617F mutation in polycythemia vera, they provide an additional degree of complexity. We demonstrated that macrophage depletion in mice carrying the Jak2 V617F mutation reverses some of the key features of polycythemia vera, including splenomegaly, reticulocytosis, erythrocytosis and elevated hematocrit. Furthermore, we showed that the proliferation of erythroid cells derived from patients harboring the JAK2 V617F mutation was increased when they were cocultured with macrophages. Thus, we propose a model for polycythemia vera progression in which the JAK2 V617F mutation initiates pathology, but a permissive niche and SEMA are required for full manifestation of the erythroid phenotype in vivo (Fig. 6) . This model represents a clear parallel to the current understanding of tumor biology, for which a role of tumorassociated macrophages supporting tumor progression and metastatic spread is now uncontested 55 .
The four hallmarks of erythropoiesis in β-thalassemia are (i) increased cell proliferation; (ii) ineffective cell differentiation, associated with modulation of the Jak-Stat pathway [37] [38] [39] ; (iii) reduced survival of erythroblasts; and (iv) limited RBC lifespan 37 . All of these features are modulated by macrophages, making interpretation of our studies more complicated. Our data indicate that macrophage depletion directly influences erythroid development in β-thalassemia by decreasing erythroid proliferation and increasing erythroid differentiation, leading to reduced reticulocytosis (as in stress erythropoiesis and polycythemia vera mice), splenomegaly and EMH. The effect on erythroid expansion and splenomegaly is apparent very soon after macrophage depletion, pointing to a direct effect of macrophages in modulating signaling pathways controlling erythroid proliferation and differentiation. In support of this hypothesis, we show that these effects are independent of the effects of macrophage depletion on erythroid iron availability (as tested using Hamp knockout and iron-supplemented β-thalassemic mice). Moreover, we demonstrated in human samples that macrophages directly promote erythroid proliferation and limit the enucleation of human primary erythroblasts. Clodronate treatment also impairs iron delivery to maturing erythrocytes in mice, as shown by a reduction of serum iron concentrations after clodronate administration. In line with previous work 51, 52 , limited iron availability probably contributes to a reduction in hemichrome formation and consequently an increased RBC lifespan. Thus, despite the fact that macrophage depletion in β-thalassemic mice leads to decreased reticulocyte production, RBC numbers are increased due to normalization of their survival and lifespan. Our data support a model in which macrophage depletion positively influences erythropoiesis in β-thalassemia by two distinct mechanisms: direct modulation of erythroid activity by limiting SEMA and reduced iron availability. We believe that targeting these two pathways together would be of greater therapeutic benefit than targeting each of them individually.
In summary, our data support a model in which SEMA stimulates signaling pathways that complement Epo-EpoR-Jak2 signaling and iron npg supply and are essential for erythroid expansion and differentiation. Without this support, the proliferative potential of erythroid cells diminishes substantially. Whereas loss of SEMA seems to be detrimental during anemia, it decreases the pathological features of disorders associated with enhanced erythroid activity, polycythemia vera and β-thalassemia. Our data further highlight the crucial role of the erythroid microenvironment, particularly macrophage-erythroblast interactions, in the regulation of pathological erythropoiesis and extend the relevance of our findings in human samples. Similar results are reported in the accompanying paper by Frenette and colleagues 57 , also revealing a new role of macrophages in supporting altered erythropoiesis. These findings could pave the way for the identification of new therapeutic approaches that are complementary to those currently used for these disorders.
METhODS
Methods and any associated references are available in the online version of the paper. Figure 6 Model of macrophage function in normal and pathological erythropoiesis. (a) Left, the contribution of macrophages for steady state erythropoiesis. Under these conditions, macrophages mildly support erythroid development but have a crucial function in the maintenance of serum iron availability by controlling hepcidin expression and iron recycling from senescent red cells. Right, the effect of macrophage depletion on steady state erythropoiesis. Under these conditions, erythropoiesis is only slightly reduced and there is no substantial decrease in RBC production. However, iron metabolism is impaired, leading to low iron availability, reduced hemoglobin synthesis and low MCH. Anemia arises as a consequence of low MCH. Mac, macrophage; PB, peripheral blood; Retic, reticulocyte; BM, bone marrow; Spl, spleen; Liv, liver; Fe Rec, iron recycling; Hpc, hepcidin; SI, serum iron; EF, erythroid factor. (b) Model describing ironindependent SEMA under conditions of elevated erythropoiesis associated with anemia, hrEPO administration or polycythemia vera caused by the Jak2 V617F mutation. Under conditions of normal macrophage function (left), SEMA supports erythropoiesis, functioning as a complement to EpoR-Jak2-Stat activation. This allows for high reticulocytosis and RBC production. If SEMA is abrogated (right), erythroid expansion is markedly impaired, leading to low reticulocytosis. Moreover, iron availability is also decreased, further contributing to an impaired erythroid response. Whereas the function of macrophages might be crucial during recovery from anemia, it seems to have a decisive role in the pathophysiology of polycythemia vera, contributing to high erythrocytosis. (c) Contribution of macrophages to the pathophysiology of β-thalassemia. In β-thalassemia, erythropoiesis is characterized by increased erythroid proliferation and decreased differentiation, which is SEMA dependent (left). Right, the model of erythropoiesis in the absence of macrophages. Under these conditions, there is an improvement of erythropoiesis due to a decrease in erythroid proliferation and an improvement of erythroid differentiation. As macrophage depletion is protracted over time by repeated administration of clodronate, erythroid iron availability decreases, further contributing to the phenotypic improvement of β-thalassemic RBCs. TAU gel was adjusted taking into account CBC readings so that the same number of RBCs (150 × 10 6 ) was loaded in each lane.
Expansion of human CD34 + hematopoietic progenitors. Blood samples from healthy donors and from patients with polycythemia vera or β-thalassemia were obtained under IRB-approved protocols. All experiments were approved by Weill Cornell Medical College and Memorial Sloan-Kettering Cancer Center ethical committee and were conducted after informed consent of all participants. Peripheral blood mononuclear cells (PBMCs) from these blood samples were separated using a ficoll gradient and after extensive washing with PBS were resuspended in 600 µl of 1% BSA in PBS. We then added 100 µl of anti-human CD34 beads for 15 min at 4 °C, after which we passed the cells through an LS magnetic column (Miltenyi Biotech) according to manufacturer's instructions. Eluted CD34 − cells were processed for macrophage differentiation (see below). CD34 + cells trapped in the column were collected by removing the LS column from the magnetic field and eluting with 5 ml of beading buffer. We expanded CD34 + hematopoietic progenitors in StemSpan supplemented with 1% of CC100 cytokine cocktail (Stem Cell technologies), 2 U/ml of hrEPO, 100 µg ml −1 of streptomycin, 100 U ml −1 penicillin and 10 −6 M dexamethasone. CD34 + cells were expanded for up to 3 weeks at low confluency (0.5-1 × 10 6 ml −1 ) to prevent their differentiation.
Differentiation of human macrophages. CD34 − PBMCs from healthy individuals and patients with polycythemia vera or β-thalassemia were resuspended in RPMI complete (RPMI, 10% FBS, 100 µg ml −1 of streptomycin and 100 U ml −1 penicillin) supplemented with 10 ng ml −1 of human recombinant macrophage colony stimulation factor (hrM-CSF; Peprotech, Rocky Hill, NJ) at 3 × 10 6 cells ml −1 . We plated 3 ml of PBMC suspension in each well of six-well plates, and monocytes were allowed to adhere to the plastic overnight at 37 °C in 5% CO 2 . The next day, we carefully removed the supernatant and replaced it with 3 ml of macrophage differentiation medium (RPMI complete supplemented with 25 ng ml −1 of hrM-CSF). The medium was changed every 3 d, and macrophages were allowed to differentiate for 7-10 d.
Erythroid differentiation of human CD34 + hematopoietic progenitors. For erythroid differentiation, human CD34 + cells were grown for up to 3 weeks as described above, washed with PBS and resuspended in human erythroid differentiation medium (α-minimum essential medium, 30% HyClone FBS, 100 µg ml −1 of streptomycin, 100 U ml −1 penicillin, 14 µM 2-mercaptoethanol, 10 U ml −1 of hrEPO and 1 ng ml −1 of stem cell factor) at 10 6 cells ml −1 . Erythroid differentiation was carried out for 8 d in six-well plates in the presence or absence of differentiated macrophages. During differentiation, we kept the cells at 2-4 × 10 6 cells ml −1 by cell counting and refreshed the medium at days 4, 6 and 8. Analyses of erythroid differentiation markers, cell cycle, apoptosis and enucleation were performed at these time points by flow cytometry (see below).
Flow cytometry of human erythroid cells. Differentiating human erythroid cells were stained with the differentiation markers PE-labeled CD117 (eBioscience, cat. number 12-1178-42; 1:20 dilution), APC-labeled GPA/CD235a (BD Pharmingen, cat. number 551330; 1:100 dilution), PE-conjugated CD44 (BD Pharmingen, 553134; 1:100 dilution) and FITC-conjugated Band-3 for 15 min on ice (a generous gift from N. Mohandas, New York Blood Center; 1:20 dilution). Cell cycle analysis was performed with the APC-BrdU flow kit (BD) according to the provided protocol. Apoptosis staining with annexin V and 7-AAD was performed as described above (in the flow cytometry analysis of mouse erythroid cells section). All samples were analyzed in a FACSCalibur (BD) instrument equipped with a dual laser.
Serum iron content. Serum iron and transferrin saturation were determined using the Iron/UIBC kit from Thermo Electron (Melbourne, Australia) as previously described 60 .
Serum EPO concentrations. Serum EPO concentrations were determined by ELISA using the kit from R&D Biosystems (Minneapolis, MN) according to the instructions provided.
Immunohistochemistry. Tissues were fixed in 10% buffered formalin and embedded in paraffin. Longitudinal sections (4 µm) were stained with H&E as previously described 60 . Immunohistochemistry was performed on splenic sections from clodronate-and PBS-treated Hbb th3/+ mice using a purified antibody to F4/80 (eBioscience, cat. number 14-4801) at a 1:100 dilution on a BONDmaXAutomated Immunostainer (Vision BioSystems, Melbourne, Australia).
Quantitative real-time PCR. We extracted RNA from liver samples using the TRIzol reagent (Sigma, St. Louis, MO) according to the instructions provided. We then quantified RNA samples and used 3 µg of total RNA for retrotranscription using the SuperScript III kit (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. Quantitative PCR for mouse hepcidin and for the internal control, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), was performed as previously described 60 .
Statistical analyses. Statistical differences were calculated with Student's t test (Microsoft Excel).
